On January 19, 2016, Ronald Levy, M.D., the Robert K. Summy and Helen K. Summy Professor of Medicine and Director of the Lymphoma Program at Stanford University School of Medicine, discussed current immunotherapy treatment options for patients with leukemia and lymphoma, such as monoclonal antibodies, chimeric antigen receptor (CAR) therapy, checkpoint blockade, and combination therapies, and how close we are to making these treatments available to more patients.
Dr. Levy is also the Associate Director of Translational Science for the Stanford Cancer Institute. For more than 25 years, his research has focused on the study of lymphoma. He was the first to successfully treat cancer with a monoclonal antibody, and went on to help develop rituximab (Rituxan®) for the treatment of patients’ lymphomas. Dr. Levy has published over 300 articles in the fields of oncology and immunology. In 1982, Dr. Levy shared the first Armand Hammer Award for Cancer Research, and was later awarded the ASCO Karnofsky Award, General Motors Charles Kettering Prize, Medal of Honor (American Cancer Society), and the 2004 Damashek Prize (American Society of Hematology). In 2009, he was elected to the National Academy of Sciences and won the King Faisal International Prize in Medicine.
This webinar is part of the Cancer Research Institute's webinar series, "Cancer Immunotherapy and You," which are offered free to the public and feature informative updates for patients and caregivers from leaders in cancer immunotherapy, followed by a Q&A. This series is presented by LabAnswer and its employees, Celldex Therapeutics, and Regeneron. For more information on this webinar, or to register for upcoming webinars, please visit www.cancerresearch.org/webinars.